Tringale Kathryn R, Grommes Christian, Ucpinar Burcin A, Reiner Anne S, Yahalom Joachim, Cederquist Gustav Y, Schaff Lauren R, Hatzoglou Vaios, Young Robert J, Payinkay Mousa, Bartlett Grace, Scordo Michael, Imber Brandon S, Schefflein Javin
Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York.
Int J Radiat Oncol Biol Phys. 2025 Apr 1;121(5):1248-1257. doi: 10.1016/j.ijrobp.2024.11.088. Epub 2024 Nov 28.
In primary central nervous system lymphoma (PCNSL), the extent to which post-methotrexate consolidation contributes to neurotoxicity is unclear. Concerns for neurotoxicity from standard dose whole-brain radiation therapy (WBRT) have led to declining use. Cerebral atrophy is an established surrogate for neurotoxicity; however, the relative extent to which modern consolidation (ie, reduced-dose [RD-]WBRT ≤24 Gy, autologous hematopoietic cell transplant) contributes to cerebral atrophy is unclear.
Patients with PCNSL from 2000-2020 who achieved a complete response to consolidation following methotrexate-based induction were included. Inclusion criteria were preconsolidation magnetic resonance imaging (baseline) and ≥1 magnetic resonance imaging showing sustained remission at 1, 3, 5, or 10 years. An expert neuroradiologist longitudinally measured parenchymal volume loss via ventricular volumetric change. Linear mixed-effects models were performed to estimate absolute and annual volumetric change rates.
Of 139 patients (median follow-up, 4.5 years), most were Memorial Sloan Kettering Cancer Center (MSK) recursive partitioning analysis (RPA) class 2 (age ≤50 years, Karnofsky performance score (KPS) ≥70). Consolidation therapies included nonmyeloablative chemotherapy (n = 57; 41%), high-dose myeloablative chemotherapy with autologous hematopoietic cell transplant (n = 50; 36%), and RD-WBRT (n = 28; 20%). A higher MSK RPA class was associated with greater baseline ventricular volume (P < .001). Overall adjusted annual ventricular volume change rates were greater than those published in healthy controls (4.3% vs 1.8%) and generally increased by age/decade at diagnosis: 40 to 49-year-olds 1.8% (95% CI, -1.4% to 5.0%), 50 to 59-year-olds 3.1% (95% CI, 0.7%-5.5%), 60 to 69-year-olds 4.8% (95% CI, 2.4%-7.3%), 70 to 79-year-olds 7.2% (95% CI, 4.3%-10.2%), and 80 to 89-year-olds 4.2% (95% CI, -1.1% to 9.6%). There were no significant associations between consolidation strategy and ventricular volume change rates accounting for age, KPS, gender, baseline ventricular volume, or interaction between age and consolidation.
These findings demonstrate accelerated cerebral atrophy in PCNSL after consolidation compared with healthy adults. However, atrophy did not differ by consolidation strategy. These long-term results suggest acceptable neurotoxicity following RD-WBRT.
在原发性中枢神经系统淋巴瘤(PCNSL)中,甲氨蝶呤巩固治疗对神经毒性的影响程度尚不清楚。对标准剂量全脑放疗(WBRT)神经毒性的担忧导致其使用减少。脑萎缩是公认的神经毒性替代指标;然而,现代巩固治疗(即低剂量[RD-]WBRT≤24 Gy、自体造血细胞移植)导致脑萎缩的相对程度尚不清楚。
纳入2000年至2020年接受基于甲氨蝶呤诱导治疗后巩固治疗取得完全缓解的PCNSL患者。纳入标准为巩固治疗前的磁共振成像(基线)以及≥1次显示在1、3、5或10年持续缓解的磁共振成像。一位神经放射学专家通过脑室容积变化纵向测量实质体积损失。采用线性混合效应模型估计绝对和年度容积变化率。
139例患者(中位随访时间4.5年)中,大多数为纪念斯隆凯特琳癌症中心(MSK)递归分区分析(RPA)2级(年龄≤50岁,卡诺夫斯基功能状态评分[KPS]≥70)。巩固治疗包括非清髓性化疗(n = 57;41%)、高剂量清髓性化疗联合自体造血细胞移植(n = 50;36%)和RD-WBRT(n = 28;20%)。较高的MSK RPA分级与更大的基线脑室容积相关(P <.001)。总体调整后的年度脑室容积变化率高于健康对照人群(4.3%对1.8%),并且在诊断时通常随年龄每十年增加:40至49岁为1.8%(95%CI,-1.4%至5.0%),50至59岁为3.1%(95%CI,0.7%-5.5%),60至69岁为4.8%(95%CI,2.4%-7.3%),70至79岁为7.2%(95%CI,4.3%-10.2%),80至89岁为4.2%(95%CI,-1.1%至9.6%)。在考虑年龄、KPS、性别、基线脑室容积或年龄与巩固治疗之间的相互作用后,巩固治疗策略与脑室容积变化率之间无显著关联。
这些发现表明,与健康成年人相比,PCNSL患者巩固治疗后脑萎缩加速。然而,萎缩程度在不同巩固治疗策略之间并无差异。这些长期结果表明RD-WBRT后的神经毒性是可接受的。